Valuation Foresee Pharmaceuticals Co., Ltd.
Stocks
6576
TW0006576002
Biotechnology & Medical Research
|
End-of-day quote
Taipei Exchange
22/10/2026
|
5-day change | 1st Jan Change | ||
| 76.00 TWD | -0.65% |
|
-1.81% | -5.71% |
Company Valuation: Foresee Pharmaceuticals Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10,474 | 14,047 | 10,797 | 13,062 | 11,995 | 12,698 |
| Change | - | 34.12% | -23.14% | 20.98% | -8.16% | 5.86% |
| Enterprise Value (EV) 1 | 8,982 | 12,795 | 10,148 | 12,130 | 10,888 | 12,450 |
| Change | - | 42.45% | -20.69% | 19.53% | -10.24% | 14.34% |
| P/E | -17.8x | -24.6x | -22.8x | -11.8x | -9.84x | -14.1x |
| PBR | 5.73x | 10.7x | 11.9x | 10.5x | 7.5x | 13.7x |
| PEG | - | 6.53x | 1.3x | -0x | 2.97x | 0.5x |
| Capitalization / Revenue | 45.5x | 62.1x | 35.8x | 67x | 28.6x | 29.4x |
| EV / Revenue | 39x | 56.6x | 33.7x | 62.2x | 26x | 28.9x |
| EV / EBITDA | -20.1x | -25.7x | -23.6x | -12.8x | -10.7x | -15.3x |
| EV / EBIT | -18.5x | -23.8x | -21.6x | -12x | -10.1x | -14.4x |
| EV / FCF | -34.6x | -54.2x | -25.2x | -19.7x | -14.4x | -18.8x |
| FCF Yield | -2.89% | -1.85% | -3.96% | -5.08% | -6.92% | -5.32% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -5.04 | -4.85 | -4.004 | -8.142 | -7.872 | -5.702 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 230.4 | 226 | 301.5 | 195 | 418.7 | 431.3 |
| EBITDA 1 | -446.6 | -498.4 | -429.7 | -950.7 | -1,016 | -812.2 |
| EBIT 1 | -484.8 | -538.6 | -469.4 | -1,008 | -1,080 | -862.3 |
| Net income 1 | -510.7 | -569.3 | -472.6 | -1,036 | -1,081 | -883.2 |
| Net Debt 1 | -1,492 | -1,252 | -648.2 | -931.4 | -1,107 | -247.8 |
| Reference price 2 | 89.60 | 119.50 | 91.40 | 96.20 | 77.50 | 80.60 |
| Nbr of stocks (in thousands) | 116,898 | 117,552 | 118,124 | 135,777 | 154,779 | 157,542 |
| Announcement Date | 30/03/21 | 30/03/22 | 24/02/23 | 28/03/24 | 17/03/25 | 31/03/26 |
1TWD in Million2TWD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 367M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.59x | 5.97x | 20.28x | -.--% | 23.67B | |
| Average | 26.76x | 26.46x | 15.70x | 0.32% | 38.35B | |
| Weighted average by Cap. | 26.72x | 25.33x | 15.91x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 6576 Stock
- Valuation Foresee Pharmaceuticals Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
